Introduction
Geldanamycins (GA) are a class of anticancer drugs that inhibit tumor cell growth with demonstrated antitumor activity in mouse xenograft models of human breast cancer, melanoma, and ovarian cancer (Schulte and Neckers, 1998; Webb et al., 2000) . Moreover, drugs of the GA class can reduce the expression of several tyrosine kinase and serine kinase oncogene products, including Her2, Met, Raf, cdk4, and Akt (Schulte and Neckers, 1998; Webb et al., 2000; Ochel et al., 2001; Blagosklonny, 2002; Solit et al., 2002) . These drugs act at concentrations in the nanomolar range (nM-GAi) by inhibiting the molecular chaperone HSP90, thereby preventing proper folding of the client oncoproteins, leading to their destabilization (Webb et al., 2000; Bonvini et al., 2001; Ochel et al., 2001) .
The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), contribute to tumorigenesis and metastasis (Birchmeier et al., 2003) . Inappropriate Met expression is highly correlated with metastasis and reduced overall survival of patients with cancer (Maulik et al., 2002b; Birchmeier et al., 2003) , and both Met and HGF/SF have been implicated in many types of human and animal carcinomas and sarcomas ohttp://www.vai.org/metandcancer/>. Met signaling induces proliferation and invasion in vitro and tumorigenesis and metastasis in animal models. HGF/SF is a potent angiogenic and survival molecule (Birchmeier et al., 2003) . One consequence of Met activation by HGF/SF is induction of the urokinase-type plasminogen activator (uPA) proteolysis network, an important factor in tumor invasion and metastasis. Exposure of Met-expressing cells to HGF/SF induces the expression of uPA and/or the uPA receptor, leading to plasmin production by cleavage of plasminogen (Jeffers et al., 1996; Tacchini et al., 2003; Hattori et al., 2004) . To search for drugs that might inhibit tumor cell invasion, Webb et al. (2000) developed a cell-based assay in canine kidney MDCK epithelial cells and searched for compounds that inhibit uPA activity. Several derivatives of GA inhibited uPA activity at femtomolar concentrations (fM-GAi), far below the nanomolar concentrations required to reduce Met expression (Webb et al., 2000) . These studies suggested that MDCK cells possess a novel target for fM-GAi drugs that is high in affinity and likely low in abundance.
Here, we report that fM-GAi sensitivity of the uPA proteolysis network in MDCK cells is HGF/SF dependent, and that such sensitivity is present as well in human tumor cell lines for which uPA activity can be significantly upregulated by HGF/SF. In addition to inhibiting HGF/SF-mediated uPA induction, we found that fM-GAi compounds also inhibit HGF/SF-induced scattering of MDCK cells and invasion of human DBTRG, SNB19 and U373 glioblastoma cells in vitro. However, circumstantial evidence indicates HSP90 is not the fM-GAi target. First, not all HSP90-binding compounds display fM-GAi activity. Radicicol (RA), which binds to HSP90 with high affinity (Roe et al., 1999; Schulte et al., 1999) inhibits HGF/SF-induced uPA activation at nothing lower than nanomolar levels. Macbecin II (MA), an nM-GAi drug, and GA, an fM-GAi drug, both inhibit uPA activity and Met expression in parallel manner at nanomolar concentrations. With MDCK and DBTRG cells in nanomolar concentrations of these drugs, available HSP90 binding sites are occupied. However, at picomolar and lower concentrations of GA, with HSP90 and Met protein levels unaffected, uPA activity, MDCK cell scattering, and DBTRG tumor cell invasion are still inhibited. Thus, fM-GAi drugs are potent inhibitors of HGF/SFmediated tumor cell invasion do not appear to function through HSP90.
Results

GAs are potent inhibitors of HGF/SF-induced uPA activity in human cells
Previously, certain GA derivative compounds were shown to inhibit HGF/SF-induced uPA activity in MDCK cells at femtomolar concentrations (Table 1) (Webb et al., 2000) . The most active derivatives, called fM-GAi compounds, are those in which the 17-methoxy group of GA has been replaced by an amino or an alkylamino group (Wenkert et al., manuscript in preparation) . To determine whether, like MDCK cells, human tumor cell lines display fM-GAi sensitivity, we first screened several cell lines for HGF/SF-inducible uPA activity (Table 2) . As expected from previous work, high levels of uPA activity were induced in MDCK cells by HGF/SF. However, we also identified four human tumor cell lines that exhibited HGF/SF-inducible uPA activity, namely three glioblastoma multiforme (GBM) cell lines (DBTRG, U373, and SNB19) and the highly invasive SK-LMS-1 leiomyosarcoma cells (Jeffers et al., 1996; Webb et al., 2000) . We performed detailed fM-GAi concentration-inhibition testing of the compounds listed in Table 1 on the cell lines in Table 2 . We used RA and MA as examples of drugs that inhibit uPA activation in the nanomolar range. MDCK cells, as previously characterized by Webb et al. (2000) , were used as a control for fM-GAi drug sensitivity and showed the same sensitivity as reported previously (Figure 1 , panel a) Importantly, we found that only human tumor cell lines that exhibit at least a 1.5-fold level of uPA activation following exposure to HGF/SF (Table 2) were similar to MDCK cells in terms of fM-GAi sensitivity (Figure 1 , panels b (DBTRG), c (U373), and d (SNB19), and data not shown). None of the compounds exhibited significant effects on cell proliferation ( Figure 1 , panels e-g). The fM-GAi compounds showed dose-dependency curves extending over a broad concentration range in each cell line, with inhibitory effects for 17-(N-allylamino)-17-demethoxygeldanamycin (17-AAG) in MDCK and U373 cells observed at concentrations as low as 10 À17 M.
These findings confirm that sensitivity to fM-GAi compounds is not a peculiar feature of a particular cell line. However, it also appears that fM-GAi drugs are uPA-plasmin inhibition index or IC 50 is the negative log 10 of the drug concentration at which 50% inhibition of uPA occurs (Webb et al., 2000) . Compounds with IC 50 values higher than 12 are referred to fM-GAi, while compounds with index lower than 8 belong to nM-GAi To measure HGF/SF-inducible uPA activity, cells were seeded in 96well plates. After 24 h, HGF/SF was added to triplicate wells at final concentrations of 0, 10, 20, 40, and 60 ng/ml and uPA activity was measured after an additional 24 h of incubation. The values shown are the mean ratios of peak uPA induction observed following HGF/SF exposure to basal uPA activity for each cell line. Asterisks (*) indicate those cells lines which display fM-GAi sensitivity (Figure 1 , data not shown)
Geldanamycins inhibit HGF/SF-mediated tumor cell invasion Q Xie et al only effective in cells that attain at least a 50% induction of uPA activity in response to HGF/SF exposure. In some of the sensitive GBM cell lines, notably DBTRG cells, we also observed a reduction in baseline uPA activity in response to fM-GAi compounds (data not shown). This could be related to low-level autocrine Figure 1 Effects of GA and related compounds on uPA inhibition in human tumor cell lines. Cells were incubated for 24 h with 60 U/ ml HGF/SF in the absence or presence of various concentrations of GA and related compounds as indicated. The uPA activity assay was performed on MDCK cells essentially as described previously (Webb et al., 2000) . Proliferation was measured by the MTS assay as described in 'Materials and methods'. Normalized uPA (or normalized growth) represents the respective assay results from drugtreated cells normalized to the mean value obtained from cells stimulated with HGF/SF in the absence of drug and expressed as a percentage of control. Values displayed represent mean values71 s.d. from triplicate assays at each concentration of each test compound. MDCK cells, panel a; DBTRG cells, panels b and e; U373 cells, panels c and f; SNB19 cells, panels d and g. Test compounds included RA and MA and were used at the indicated concentrations. GA derivatives are abbreviated as follows: GA ¼ geldanamycin; 17-AAG ¼ 17-allylamino-17-demethoxygeldanamycin and 17-ADG ¼ 17-amino-17-demethoxygeldanamycin HGF/SF-Met signaling found in some GBM cells (Koochekpour et al., 1997) . RA and MA inhibited HGF/SF-mediated induction of uPA activity only at nanomolar and higher concentrations. RA, which displays a much higher binding affinity to HSP90 than GA (K d ¼ 19 nM vs 1.2 mM; (Roe et al., 1999; Schulte et al., 1999) ), only exhibits inhibition of HGF/SF-mediated uPA activity at nanomolar concentrations. These findings indicate that, while HSP90 may be a molecular target for nM-GAi compounds, it probably does not account for fM-GAi activity in sensitive cells.
fM-GAi and HGF/SF-induced scattering and invasion
We next tested whether, in addition to inhibition of uPA activity, fM-GAi compounds affect biological activities of cell scattering and tumor cell invasion in vitro. We found that GA itself and 17-AAG inhibit HGF/SFinduced MDCK cell scattering in the picomolar to femtomolar range ( Figure 2A ). Moreover, as shown in Figure 2B -D, even at picomolar to femtomolar concentrations, GA abolished HGF/SF-induced Matrigel invasion by the highly invasive DBTRG, SNB19, and U373 human GBM cells. The marked inhibition of invasion, evident even in the femtomolar range, closely paralleled the inhibitory effects of fM-GAi toward HGF/SF induction of uPA activity (cf. Figure 1) .
Further evidence for a molecular target other than HSP90 that accounts for fM-GAi activity Previous work in our laboratory showed that GA inhibited urokinase-type plasminogen activator receptor (uPAR) expression and Met expression in SK-LMS-1 and MDCK cells at nanomolar or higher concentrations (Webb et al., 2000) , compared to the femtomolar range where uPA activity inhibition occurs. We tested the sensitivity of Met and HSP90a expression to GA and MA in cell lines sensitive to fM-GAi compounds ( Figure 3 ). As others have reported, at nanomolar levels GA upregulates HSP90a (Nimmanapalli et al., 2001) and downregulates Met expression (Webb et al., 2000; Maulik et al., 2002a) (Figure 3 , lanes 5 and 11 for MDCK and DBTRG cells, respectively). However, no significant changes were observed in the relative abundance of either HSP90a or Met at the subnanomolar concentrations of fM-GAi compounds like GA (Figure 3 , lanes 6 and 12), at which uPA activity or scattering or in vitro invasion are inhibited (cf. Figures 1  and 2 ). GA upregulation of HSP90a and downregulation of Met were observed at 10 À5 M MA (Figure 3 , lanes 3 and 9), but less response was observed at 10 À6 M levels (Figure 3 , lanes 4 and 10). Importantly, negligible levels of HSP90a were pulled down with GA-affinity beads at 10 À5 M MA and 10 À6 M GA ( Figure 3 , lanes 3, 5, 9, and 11), respectively, and the available HSP90a to the GAaffinity beads was also reduced with 10 À6 M MA (Figure 3, lanes 4 and 10) . These results show that both drugs in the cell lysate effectively compete to prevent association of HSP90 with the bead form of the GA, showing that the available binding sites are blocked. From these results, we conclude that at subnanomolar concentrations of GA, no effect is observed on Met or HSP90a expression. Moreover, the nM-GAi drug MA, like GA, effectively competes with HSP90a binding to GA-affinity beads, even though MA lacks fM-GAi activity. Our results imply that the subnanomolar inhibitory effects of fM-GAi compounds cannot involve binding in any stoichiometrically significant way to HSP90a.
Analysis of MDCK cells chronically exposed to MA
From the preceding experiments showing that HSP90a in MA-treated cells is unavailable to GA-affinity beads, we expected that if we maintained MDCK cultures chronically on MA at the highest nontoxic level, the binding sites on HSP90a and other nM-GAi targets would be occupied and we could test whether these cells were still sensitive to fM-GAi compounds.
We used MA and tested several high concentrations, but only show the highest nontoxic levels that MDCK cells were able to grow. MDCK cells were cultured long term in medium containing MA at 1, 2, and 3 Â 10 À6 M concentrations to generate MDCKG1, MDCKG2, and MDCKG3 cells, respectively. MDCK cells continued to proliferate at MA concentrations up to, but not above, 3 Â 10 À6 M. All of the cell lines grew well in the presence of MA, albeit at slower rates than parental cells (data not shown). The responses of cell lines chronically exposed to MA and to an acute challenge with 10 À6 M GA or 10 À5 M MA are displayed in Figure 4 . Cells maintained in 1-2 Â 10 À6 M MA (MDCKG1-G2) exhibited normal levels of both Met and HSP90 ( Figure 5 , lanes 2, and 5), while Met abundance was somewhat lower in MDCKG3 cells (maintained in 3 Â 10 À6 M MA) than in parental cells (cf. Figure 4 , lanes 1 and 8). Upon acute challenge for 24 h with GA, all of the cell lines chronically exposed to MA showed dramatic decreases in Met abundance ( Figure 4 , lanes 3, 6, and 9), with less of a decrease evident upon challenge with 10 À5 M MA itself, especially with MDCKG2 and -G3 cells (Figure 4 , lanes 7 and 10). Acute increases in HSP90a were suggested in MDCKG1 and -G2 cell lines upon challenge with GA, but not in MDCKG3 cells. From these results we expect that the MDCKG3 are made at least partially tolerant to 10 À6 M GA, while MDCKG1 and G2 are less so and, in large measure, are more like the parental cells (Figures 3 and 4 ).
Met function in cells chronically exposed to MA
To assess whether MA-treated MDCKG3 cells still retain their sensitivity to GA, we first tested whether Met remained functional in cells chronically exposed to MA, as measured by HGF/SF-induced downstream signaling ( Figure 5 We show that MDCKG3 cells still scatter in response to HGF/SF even in the presence of 3 Â 10 À6 M MA ( Figure 6A , panels d and e), while the same concentration of MA on MDCK cells effectively blocks scattering ( Figure 6A , panel c). We further tested GA inhibitory activity at 10 À7 to 10 À15 M on HGF/SF-induced cell scattering in MDCKG3 cells ( Figure 6A ): Only at 10 À15 M GA was scattering again fully observed ( Figure 6A , panel i), showing that exquisite sensitivity to fM-GAi persists even in MDCKG3 cells maintained in 3 Â 10 À6 MA.
We also tested whether Met remained functional in MDCKG3 cells chronically exposed to MA, as measured by HGF/SF-induced downstream uPA induction ( Figure 6B ). Just as in parental MDCK cells, GA was a far more potent inhibitor of HGF/SF-induced uPA activity than MA, effective at 10 À13 M in MDCKG3 cells. Taken together, these findings show that Met in MDCKG3 cells is fully responsive to HGF/SF in signaling through Erk1 and Erk2, in scattering assays, and in terms of uPA induction. Figure 2 Effects of GA on MDCK scattering and DBTRG invasion in vitro. (A) For the scattering assay, MDCK cells were seeded in 96-well plates at 1500 cells/well in triplicate. After 24 h, HGF/SF (100 ng/ml) was added alone or in the presence of GA: After 24 h, culture medium was discarded, and cells were fixed and stained using Diff-Quik stain set. Representative micrographs of the variously treated MDCKcell preparations are shown: MDCK cells (a-j); HGF/SF-treated cells (b-j); plus GA at 10 À7 M in (c); GA at 10 À9 M in (d); GA at 10 À13 M in (e); GA at 10 À15 M in (f); 17-AAG at 10 À7 M (g); 17-AAG at 10 À9 M in (h); 17-AAG at 10 À13 M in (i); and 17 AAG at 10 À15 M in (j). (B-D) Invasion in vitro of DBTRG (B), SNB19 (C) and U373 (D) cells were measured by the Matrigel invasion assay. Cells (DBTRG 5000, SNB19, and U373 25 000 cells/well) were seeded into the upper chambers in DMEM without serum. Immediately after seeding, HGF/SF (100 ng/ml) was added to the lower chambers, except for the minus HGF/SF control (designated '0'). GA at different concentrations was added to both upper and lower chambers. Cells penetrating the Matrigel layer were counted after drug exposure for 24 h. Each bar represents the mean for cell counts from triplicate samples71 s.d.
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Discussion
It is well known that HGF/SF-induced uPA activity is correlated with tumor invasion and metastasis in many types of solid tumors. When Met signaling is initiated by HGF/SF, both uPA and uPAR expression are upregu-lated and plasminogen is consequently cleaved into plasmin, a sequence of events that results in degradation of the extracellular matrix (Ellis et al., 1993) . High levels of uPA and uPAR expression are associated with poor clinical prognosis (Duffy, 1996; Duffy et al., 1996; Harbeck et al., 2002) , and uPAR-targeted anticancer strategies are being developed Lakka et al., 2003; Schweinitz et al., 2004) . Our laboratory previously developed a cell-based method for screening HGF/SF-induced uPA-plasmin network inhibitors and, by using this assay, discovered that ). An aliquot of each cell lysate was also incubated with GA-affinity beads as described in 'Materials and methods', and eluates from the beads were analysed by SDS-PAGE followed by immunoblotting with antibody against HSP90a. Control cultures received no HGF/SF and no test compound. Relevant regions of the resulting fluorograms are shown: Samples for lanes 1-6 and 7-10 are, respectively, from MDCK and DBTRG total cell lysates. HSP90a was detected in pull-down experiments with GA gel beads (upper panel) or in whole-cell lysates in Western blots with anti-HSP90a antibody (second panel). Samples used for lanes 2-6 and 8-12 were from cells treated with HGF/SF. Samples for lanes 3, 4, and 9, 10 were from cells treated with MA as indicated; samples for lanes 5, 6, and 11, 12 are from cells treated with GA as indicated Figure 4 Effects of long-term MDCK cell culture in MA on sensitivity of Met and HSP90a to nM-GAi and fM-GAi drug challenge. MDCK cells were maintained for 2-3 months in MA at concentrations ranging from 1 to 3 Â 10 À6 M to generate MDCKG1(10 À6 M), MDCKG2(2 Â 10 À6 M), MDCKG3(3 Â 10 À6 M) cells, respectively. For drug challenge, parental MDCK cells or long-term-exposed cells (1 Â 10 6 ) were seeded in 100 Â 20 mm 2 dishes, grown to 80% confluency, and then further exposed to either GA ( þ GA, 10 À6 M) or MA ( þ MA, 10 À5 M) for 24 h. Cells were harvested and lysed, and lysates were analysed for relative abundance of Met, HSP90a, and b-actin (loading control) by SDS-PAGE followed by immunoblotting with the antibodies as listed in Figure 3 . Relevant regions of the resulting fluorograms are shown Figure 5 HGF/SF-Met signaling in cell cultures exposed longterm to MA. A total of 2.5 Â 10 5 cells of parental MDCK cells and MA maintained MDCKG3 cells were seeded in 60 Â 15 mm 2 dishes and exposed to HGF/SF (100 ng/ml) 24 h later. At the indicated times, cells were harvested, lysed, and lysates were analysed for relative abundance of total and phosphorylated Met, total and phosphorylated Erk1, Erk2, and b-actin (loading control) by SDS-PAGE followed by immunoblotting with appropriate antibodies as listed in Figure 3 After an additional 24 h of incubation, cells were washed twice with DMEM, and 200 ml of reaction buffer containing the plasmin-sensitive chromophore was added to each well. The plates were then incubated at 371C, 5% CO 2 for 4 h, at which time the absorbances generated were read on an automated spectrophotometric plate reader at a single wavelength of 405 nm
Geldanamycins inhibit HGF/SF-mediated tumor cell invasion Q Xie et al fM-GAi compounds can inhibit HGF/SF-induced uPAplasmin proteolysis at femtomolar concentrations in MDCK cells (Webb et al., 2000) . Here, we show that not only uPA-plasmin activity but also HGF/SF-induced MDCK cell scattering can be inhibited by fM-GAi at femtomolar level (Figure 2A) . MDCK cells show the best response to HGF/SF in scattering and in uPAplasmin induction in Table 2 . We also tested DA3 cells, (a mouse mammary cancer cell line), and DU145 (a human prostate cancer cell line), for scattering sensitivity to fM-GAi drugs. Both cell lines scatter in response to HGF/SF, but uPA activity is not induced by HGF/SF and scattering is only inhibited at nanomolar concentrations. However, in GBM cells, HGF/SF-inducible scattering and uPA-plasmin upregulation are somehow linked to the fM-GAi sensitivity as indicated from the data in Table 2 and Figure 1 . MDCK cells remain the best system for detecting fM-GAi effects on scattering until we have a better understanding of the mechanisms involved.
We show here that fM-GAi-mediated uPA inhibition occurs in four human tumor cell lines that respond to HGF/SF, and is therefore not peculiar to MDCK cells. In the sensitive cell lines, uPA activity is upregulated by HGF/SF by at least 1.5-fold, a level that is probably necessary for reliably measuring fM-GAi inhibition. In fM-GAi-sensitive GBM cell lines, we also observe a reduction in baseline uPA activity. This reduction does not occur in insensitive cell lines such as prostate cancer cell lines, even though the baseline levels of uPA activity are higher in these cells than in the sensitive cell lines (data not shown). Many GBM cell lines express HGF/ SF and Met in an autocrine manner (Koochekpour et al., 1997) , whereas none of the insensitive cells do. Thus, the exquisite activity of the fM-GAi drugs directed at an HGF/SF-induced pathway is a possible explanation for the reduction in baseline. In addition, the fM-GAi compounds inhibit HGF/SF-induced scattering in MDCK cells and invasion in vitro in all three sensitive GBM cells in parallel with uPA inhibition, supporting their relatedness in tumor invasion and metastasis.
The GA drug family at nanomolar concentrations inhibit tumor growth by interfering with HSP90a chaperone function, leading to degradation of improperly folded oncoproteins Whitesell and Cook, 1996; Stebbins et al., 1997) . Most of the identified cellular oncoproteins bind to HSP90 via the amino-terminal ATP binding domain, which is also the GA binding domain Mimnaugh et al., 1996; Schneider et al., 1996; Schulte et al., 1997) . Typically, in cells treated with nanomolar concentrations of GA, HSP90 expression is upregulated and oncoproteins are degraded within 24 h. GA treatment induces oncoprotein degradation within 6-24 h (Liu et al., 1996; Tikhomirov and Carpenter, 2000; Nimmanapalli et al., 2001; Yang et al., 2001; Maulik et al., 2002a) , accompanied by upregulation of HSP90a expression (Nimmanapalli et al., 2001) . Yet, in the human small cell lung cancer (SCLC) cell line, GA treatment results in Met degradation even when HSP90 expression does not change (Maulik et al., 2002a) . In contrast, we find that scattering, invasion, and uPA activity are inhibited by fM-GAi compounds at concentrations resulting in neither HSP90 upregulation nor Met downregulation. We also find that fM-GAi compounds inhibit uPA activity even when added up to 4 h after HGF/SF addition (data not shown), even though phosphorylation of key signaling components occurs as early as 10 min after HGF/SF addition. Therefore, fM-GAi inhibition must occur downstream to Met signaling.
RA, with a higher HSP90 binding affinity than GA, only shows nM-GAi uPA inhibition. RA binds to the same ATP pocket of HSP90 as GA, but with higher affinity (Roe et al., 1999; Schulte et al., 1999) . This finding suggests that fM-GAi compounds inhibit HGF/ SF-induced uPA activity, MDCK cell scattering, and tumor cell invasion through non-HSP90 targets, and the concurrent inhibition of these three activities suggests that fM-GAi drugs are likely to target a common step in the HGF/SF-regulated migration/invasion pathway. From the data presented here, we cannot exclude the possibility that there is a rare subset of HSP90 chaperones that are responsible for the fM-GAi inhibition. For example, Eustace et al. (2004) have shown that an HSP90a isoform has an essential role in cancer invasiveness, and that this isoform is expressed extracellularly and interacts outside the cell to promote MMP2 activation. To test whether this form of HSP90a was possibly also responsible for the sensitive uPA, we used GA beads in the uPA assay. Inhibition of HGF/ SF-induced uPA activity with extracellular GA affinity beads only occurred at 10 À5 M, showing that femtomolar level inhibition of uPA is not related to HSP90a extracellular isoform. Our results indicate that there is a novel molecular target for fM-GAi drugs.
SBMs are highly invasive tumors, and HGF/SF stimulation of the uPA-plasmin network has been found to be a key process in GBM invasion Rao, 2003) . These tumors infiltrate normal brain tissue and propagate along blood vessels, such that it is impossible to completely resect them. In all, 80% of GBM tumors express HGF/SF, while 100% overexpress Met (Birchmeier et al., 2003) . uPA activity was found to be higher in astrocytomas (particularly in glioblastomas) than in normal brain tissue or in low-grade gliomas (Yamamoto et al., 1994; Gladson et al., 1995; Bhattacharya et al., 2001) , and elevated uPA expression is a poor prognostic indicator (Zhang et al., 2000) . Therefore, drugs that target Met and uPA may be important for new therapeutic strategies (Rao, 2003) . Our previous study measured the invasive potential in several GBM cell lines and DBTRG and U373 were the most invasive ones (Koochekpour et al., 1997) . SNB19 cells are also a highly invasive cell line used for GBM studies . Our study finds that all three invasive GBM cell lines show fM-GAi inhibition of HGF/SF-induced uPA activity and invasion at extremely low concentrations. 17-AAG is currently in clinical trials for several different cancers (Blagosklonny, 2002; Goetz et al., 2003) but not in glioblastoma. Our studies suggest that fM-GAi drugs might be useful in the treatment of GBM brain cancer.
Materials and methods
Cell lines and drugs MDCK (canine kidney epithelial cells), DBTRG, U373, U118, SW1783 (human glioblastoma cells), SK-LMS-1(human leiomyosarcoma cells) were purchased from ATCC. DU145 and PC-3 (human prostate cancer cells) were gifts from the laboratory of Dr Han-Mo Koo, Van Andel Research Institute. U87 and SNB19 human glioblastoma cells were gifts from Dr Jasti Rao, University of Illinois. SNB19 was grown in DMEM F12 medium (GibcoTM, Invitrogen Cooperation), all other cells were grown in DMEM (GibcoTM, Invitrogen Cooperation) medium. All medium were supplemented with 10% FBS (Hyclone) and penicillin and streptomycin (Invitrogen Cooperation). GA and chemical derivatives, , and MA were provided by the National Cancer Institute (NCI) or synthesized as described elsewhere (Wenkert, manuscript in preparation) . RA was purchased from Sigma. Long-term cultures (>3 months) of MDCK cells in growth medium containing MA at 1, 2, and 3 Â 10 À6 M yielded MDCKG1, MDCKG2, and MDCKG3 cells. All compounds were first diluted in DMSO at 10 À2 M, separated into small stock aliquots (5 ml), and kept at À801C until use. When used, stocks were thawed and serially diluted with DMEM/10% FBS. For long-term culture with MA, conditioned medium with the compound at 1, 2, or 3 Â 10 À6 M was changed at least twice a week.
HGF/SF-Met-uPA-plasmin cell-based assay
Cells were seeded in 96-well plates at 1500 cells/well (with the exception of SK-LMS-1 cells, which were seeded at 5000 cells/ well) in order to detect color intensity, either with MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium) (Promega) for cell growth determination or via Chromozyme PL (Boehringer Mannheim) for uPA-plasmin activity measurement. Cells were grown overnight in DMEM/10% FBS as described previously (Webb et al., 2000) . Drugs were dissolved in DMSO and serially diluted from stock concentrations into DMEM/10% FBS medium and added to the appropriate wells. Immediately after drug or reagent addition, HGF/SF (60 ng/ml) was added to all wells (with the exception of wells used as controls to calculate basal growth and uPA-plasmin activity levels). At 24 h after drug and HGF/SF addition, plates were processed for the determination of uPA-plasmin activity as follows: Wells were washed twice with DMEM (without phenol red; Life Technologies Inc.), and 200 ml of reaction buffer (50% (v/v) 0.05 U/ml plasminogen in DMEM (without phenol red), 40% (v/v) 50 mM Tris buffer (pH 8.2), and 10% (v/v) 3 mM Chromozyme PL (Boehringer Mannheim) in 100 mM glycine solution) were added to each well. The plates were then incubated at 371C, 5% CO 2 for 4 h, at which time the absorbances generated were read on an automated spectrophotometric plate reader at a single wavelength of 405 nm. uPA-plasmin inhibition index or IC 50 is the negative log 10 of the concentration at which uPA-plasmin activity is inhibited by 50% (Webb et al., 2000) . Compounds with IC 50 >12 are referred to as fM-GAi drugs (Table 1) , while compounds IC 50 o8 are referred to as nM-GAi drugs.
Proliferation assay
In parallel with uPA-plasmin detection assay, 96-well plates were used for proliferation detection with MTS (Promega). Cell preparations were the same as described for the uPAplasmin assay above, except that 15 ml MTS in PMS (phenazine methosulfate) solution (0.92 mg/ml PMS in 0.2 g KCl, 8.0 g NaCl, 0.2 g KH 2 PO 4 , 1.15 g Na 2 HPO 4 , 100 mg MgCl 2 Á 6H 2 O, 133 mg CaCl 2 Á 2H 2 O) was added into each well 24 h after drug and HGF/SF addition. The plates were then incubated at 371C, 5% CO 2 for 4 h. The absorbance was read on an automated spectrophotometric plate reader at 490 nm.
Scatter assay
In parallel with assessing uPA activity, 96-well plates of MDCK cells were used to detect cell scattering. Cell preparation is same as uPA-plasmin assay described above. At the same time as uPA activity was measured, the cells for the scatter assay were fixed, stained (Diff-Quik Set, Dade Behring AG), and photographed.
In vitro cell invasion assay
The in vitro invasion assay was performed as described previously (Jeffers et al., 1996) using a 24-well invasion chamber coated with GFR-Matrigel (Becton Dickinson). Cells were suspended in DMEM containing 0.1% BSA and were plated in the invasion chamber (5000-25 000 cells/well). The lower chamber was filled with DMEM containing 0.1% BSA with or without the addition of HGF/SF (100 ng/ml). To perform the GA inhibition test, GA was serially diluted into both the upper and lower chambers at final concentrations 1 mM, to 1 fM as indicated and immediately after HGF/SF addition. After 24 h, cells remaining in the upper chamber were removed by scraping. The cells that invaded through Matrigel and attached to the lower surface of the insert were stained using Diff-Quick (Dade Behring Inc.) and counted under a light microscope.
Western blot
Cells were seeded in 60 Â 15 mm 2 dishes at 10 5 cells per dish. At 24 h later, HGF/SF (100 ng/ml) was added to each dish. Immediately after HGF/SF addition, serially diluted GA or MA was added to the relevant dishes at the concentrations indicated, and incubated for the indicated length of time before lysis. For Met and MAPK phosphorylation detection, 10 5 cells were seeded in 60 Â 15 mm 2 dishes and serum starved for 24 h. After HGF/SF (100 ng/ml) stimulation, cells were lysed at 10 and 30 min. Control cells lacked HGF/SF stimulation. After cell lysis, protein concentration was determined by DC protein assay (Bio-rad), and equal quantities of protein were loaded and separated by SDS-PAGE and transferred Western blot to PVDF membranes (Invitrogen). After blocking with 5% dry milk, membranes were blotted with specific antibodies. Antibodies used are: Met (for MDCK cells, Met 25HZ: Cell Signaling; for DBTRG, C-28, Santa Cruz), phospho-Met (Tyr 1234/1235 rabbit polyclonal antibodies, Cell Signaling), phospho p44/42 MAPK (Thr 202/tyr 204 rabbit polyclonal antibodies, Cell Signaling), or b-actin (AC-15: ab6276, Abcam), which served as a loading control. After exposure to HRP-conjugated secondary antibody, membranes were incubated with ECL (Amersham Biosciences) and chemiluminescence signal intensity was detected by imaging analysis.
Solid-phase binding assays
GA-immobilized-affinity gel beads were prepared as follow (modification of Whitesell et al. (1994) and procedure provided by Len Neckers). GA (1.5 equivalents to affinity gel beads) was stirred with 1,6-diaminohexane (5-10 equivalents) in chloroform at room temperature. Upon the complete conversion of GA (monitored by TLC), the mixture was washed sequentially with dilute aqueous sodium hydroxide and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give 17-(6-aminohexylamine)-17-demethoxygeldanamycin as a dark purple solid (pure by 1 H NMR). The intermediate was then taken up in dimethyl sulfoxide and stirred with Affi-Gel 10 beads (Bio-Rad) for 2 h. The resulting purple GA beads were washed with dimethyl sulfoxide.
Control beads were made of affinity gel linked with a small chain analogue which does not have HSP90 affinity. Affi-Gel 10 beads (Bio-Rad) were stirred with N-(6-aminohexyl) acetamide (Lee et al., 1995) (1.3 equivalents) in dimethyl sulfoxide at room temperature for 2 h, and then washed thoroughly with dimethyl sulfoxide.
The above-obtained GA and control beads were washed in five volumes of TNESV (50 mM Tris-HCl (pH 7.5), 20 mM Na 2 MoO 4 , 0.09% Nonidet P-40, 150 mM NaCl, and 1 mM sodium orthovanadate) three times and rotated overnight in TNESV at 41C to hydrolyse any unreacted N-hydroxysuccinimide, and then rocked in 1% BSA in TNESV (1 : 10) at room temperature for at least 3 h. After washing with TNESV for three additional times, beads were resuspended in 50% TNESV and stored at À781C.
To perform affinity pull-down experiments, 5 Â 10 5 cells were seeded in 100 Â 20 dishes. After cells grew to 80% confluence, GA or MA, at various concentrations, was added to the dishes. After 24 h, cells were washed twice with PBS and lysed in TNESV buffer supplemented with Completet proteinase inhibitors (Roche Molecular Biochemicals). Protein concentration was determined by DC protein assay. Equal quantities of protein were used for Western blotting for Met and HSP90a. For pull-down assays, we added 20 ml of control or GA beads adjusted for equal concentrations to 500 ml of extract and rotated at 41C overnight. Beads were recovered by low-speed centrifugation and washed three times with TNESV. A measure of 60 ml 2 Â sample buffer was added to beads and boiled for 10 min. The samples were subjected to SDS-PAGE followed by Western blot analysis.
Abbreviations
GA, geldanamycin; 17-ADG, 17-amino-17-demethoxygeldanamycin; 17-AAG, 17-allylamino-17-demethoxygeldanamycin; MA, Macbecin II; RA, Radicicol; fM-GAi, GA and derivatives with uPA inhibitory activity in the femtomolar range; nM-GAi, GA and derivatives with uPA inhibitory activity in the nanomolar range; HGF/SF, hepatocyte growth factor/scatter factor; uPA, urokinase-type plasminogen activator.
